Bloomberg: BTC Options Traders Bet on a Rise to $300,000 by the End of June, but Prediction Market Probability Remains Cautious
Bloomberg revealed that the number of open contracts for Bitcoin call options expiring on June 27 with a strike price of $300,000 on Deribit ranks second, only behind contracts with a strike price of $110,000. The current Bitcoin price is approximately $107,000, and if it rises to $300,000, it would mean a 181% increase. Despite the optimistic market sentiment, analysts point out that without significant catalysts, it is difficult for the price to achieve such a substantial increase.
Additionally, data from Polymarket indicates that the market believes there is only a 9% probability of Bitcoin reaching $250,000 this year. Currently, Bitcoin is approaching the all-time high of $109,241.11 set on January 20. The market recovery, corporate interest, and policy support are considered the main factors driving the recent rise in Bitcoin.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cross-chain atomic transactions between Ethereum mainnet and L2
US Stock Movement | US clinical-stage biopharmaceutical company Retension Pharmaceuticals (RTSN.US) enters the US stock market, shares drop over 10% after opening
According to Jinse Finance, Retension Pharmaceuticals (RTSN.US) debuted on the US stock market on Friday and fell over 10% to $10.77 at press time, with an IPO price of $12. Retension Pharmaceuticals is a US-based clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of hypertension and other cardiovascular diseases. The company's core investigational drug, RTN-001, is a new generation phosphodiesterase 5 (PDE5) inhibitor, primarily targeting patients with uncontrolled or resistant hypertension, and is currently undergoing a Phase IIb clinical trial. This drug works by enhancing nitric oxide signaling in blood vessels to promote vasodilation and lower blood pressure. The exclusive global development license comes from French pharmaceutical giant Sanofi (SNY.US).
Chevron has suspended production operations at five facilities in the U.S. Gulf region.
Chevron (CVX.US) has evacuated personnel and shut down production operations at five facilities in the US Gulf region, while another four offshore platforms continue production.
Crypto prices
More
